Efficacy and safety of dupilumab for the treatment of adult atopic dermatitis: A meta-analysis of randomized clinical trials

Han, Yue; Chen, Yuxin; Liu, Xiaochun; Zhang, Jingxi; Su, Hui-Zhen; Wen, He; Li, Wei; Yao, Xu

doi:10.1016/j.jaci.2017.04.015

Cited by 56 publications

(53 citation statements)

References 10 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Dupilumab is a monoclonal antibody targeting the α subunit of the IL-4 receptor, blocking the signaling of cytokines IL4 and IL13, key cytokines involved in T helper (Th) 2 immunity. Dupilumab has revolutionized the treatment of AD, significantly improving clinical symptoms of AD, rapidly reducing itch, and improving patients' quality of life (33,34). Currently, the use of dupilumab in other pruritic con ditions is of great interest.…”

Section: Interleukin Antagonistsmentioning

confidence: 99%

A New Generation of Treatments for Itch

Fowler¹,

Yosipovitch²

2020

Acta Derm Venerol

View full text Add to dashboard Cite

Itch is a pesky sensation that can be difficult to eliminate. Although a mainstay of anti-itch therapy for many decades, antihistamines are not an effective therapy for patients with chronic, unrelenting itch. With a greater understanding of itch, newer treatments have been developed that are much more effective. These include drugs targeting the neural system and drugs that affect the immune system. For decades, antihistamines have been the mainstay of treatment for chronic pruritus, yet they often only work by making patients drowsy and forgetful of their itch. A new era of antipruritic drugs is quickly approaching, presenting more effective treatments for patients suffering from chronic itch. Several treatments have been developed targeting specific receptors in the nervous system, such as the transient receptor potential channels, sodium channels, neurokinin-1 receptors, opioid receptors, and many more. Additionally, antipruritic therapies developed to work on the immune system have become more targeted, leading to greater safety and efficacy measures. These include crisaborole, several interleukin antagonists, and janus kinase inhibitors. The promising results presented with these new antipruritic therapies allow physicians to be better equipped to treat their itchy patients.

show abstract

Section: Interleukin Antagonistsmentioning

confidence: 99%

A New Generation of Treatments for Itch

Fowler¹,

Yosipovitch²

2020

Acta Derm Venerol

View full text Add to dashboard Cite

show abstract

“…The genetic deletion of IL-4 resulted in a significant decrease in ear thickness measurements, and mast cell counts remained unchanged in MC903-treated IL-4 e/e mice (see Supplementary Figure S5a and b online). To address the fundamental role the IL-4/IL-13 axis in the pathogenesis of AD and the associated clinical efficacy of dupilumab (Han et al, 2017;Simpson et al, 2016), we conducted our model in mice that lacked STAT6. In these STAT6 e/e mice, the signaling of both IL-4 and IL-13 is impaired via the deletion of the common downstream transcription factor STAT6 (Kaplan et al, 1996).…”

Section: Il-4/stat6 Signaling Is Essential To the Mc903-induced Ad Phmentioning

confidence: 99%

Eosinophils Determine Dermal Thickening and Water Loss in an MC903 Model of Atopic Dermatitis

Naidoo

Jagot

Elsen

et al. 2018

Journal of Investigative Dermatology

View full text Add to dashboard Cite

Atopic dermatitis (AD) is a highly debilitating disease with significant health impacts worldwide. It has been a difficult disease to treat because of the wide spectrum of clinical manifestations. Therefore, the current clinical management strategies are nonspecific. Previous studies have documented that AD disease progression is precipitated by a combination of skin barrier dysfunction, itch, and immune dysregulation. However, the precise roles played by effector cells and cytokines have not been fully elucidated. To address this, we established a prolonged model of AD, using MC903. The phenotype of this MC903 model closely resembles the one observed in AD patients, including inflammatory parameters, barrier dysfunction, itch, and histopathological characteristics, thereby providing a platform to evaluate targets for the treatment of AD. This model exposed cells and cytokines that are critically associated with disease severity, including eosinophils, TSLP, and IL-4/IL-13. Indeed, eosinophil depletion significantly ameliorated AD pathology, most notably barrier dysfunction, to a similar extent as blocking of the IL-4/IL-13 axis by genetic deletion of STAT6. Thus, this study has identified eosinophils to be critical for the development and maintenance of AD, thereby proposing these effector cells as therapeutic targets for the treatment of AD.

show abstract

“…There is also some emerging evidence to support that it could be administrated as the first-line treatment for pemphigus (Joly et al, 2017). Recently, dupilumab, which is an anti-IL-4 receptoralpha antibody is increasingly used to treat atopic dermatitis and asthma (Han et al, 2017;Wenzel et al, 2016). Because there are some similarities between immune responses in these diseases and pemphigus, dupilumab was also suggested as a potent drug for pemphigus patients (Tavakolpour, 2016a).…”

mentioning

confidence: 99%

Tofacitinib as the potent treatment for refractory pemphigus: A possible alternative treatment for pemphigus

Tavakolpour

2018

Dermatologic Therapy

View full text Add to dashboard Cite

Pemphigus is a rare, but life-threatening autoimmune disease with a high rate of morbidity and mortality, if left untreated. After the development of corticosteroid therapy in the 1950s, the death rate for pemphigus has significantly decreased. However, finding more potent therapeutic options for refractory patients has remained a controversial topic. In the recent years, rituximab has increasingly been used for the treatment of refractory pemphigus, but some patients do not well-respond. In addition, there is a paucity of evidence to support the risk of diseases exacerbation after rituximab therapy. In this study, as a JAK1 and JAK3 inhibitor, tofacitinib has been proposed for the treatment of refractory pemphigus patients.

show abstract

Efficacy and safety of dupilumab for the treatment of adult atopic dermatitis: A meta-analysis of randomized clinical trials

Cited by 56 publications

References 10 publications

A New Generation of Treatments for Itch

A New Generation of Treatments for Itch

Eosinophils Determine Dermal Thickening and Water Loss in an MC903 Model of Atopic Dermatitis

Tofacitinib as the potent treatment for refractory pemphigus: A possible alternative treatment for pemphigus

Contact Info

Product

Resources

About